Related Experiment Video
Updated: May 29, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Disclosure of clinical trial results when product development is abandoned
Michael A Rogawski1, Howard J Federoff
1Department of Neurology, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA. rogawski@ucdavis.edu
Abstract:
Currently, sponsors are not required to report the outcomes of clinical research on drugs or devices that do not lead to an approved product. Consequently, the public cannot benefit from scientific information derived from all failed or abandoned drugs and devices. Provisions in the U.S. Food and Drug Administration Amendments Act of 2007 provide an opportunity for the Department of Health and Human Services to rectify this situation. By reporting the results of clinical trials of abandoned products in a publicly accessible database and in the peer-reviewed journal literature, sponsors would satisfy a core ethical obligation of clinical research and enhance translational science.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Preclinical Development: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Investigation of Disease Outbreaks
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinically Relevant Drug Product Specifications: Methods of Establishment

